BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 28 2025
0mins
Source: Globenewswire
TILsRx Platform Overview: BriaCell Therapeutics and its subsidiary BriaPro are developing the TILsRx platform, which utilizes multivalent technology to target multiple cancer-associated pathways and enhance tumor-infiltrating lymphocyte (TIL) activation while minimizing immune suppression and T cell exhaustion.
Clinical Development Goals: The platform aims to create highly selective and effective immunotherapies for various cancers, with early agents targeting B7-H3, and is expected to improve clinical responses through enhanced manufacturing efficiency and potential synergy with existing cancer vaccine programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
